ReviewNature reviews. Disease primers2020
Lupus nephritis.
Review in Nature reviews. Disease primers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 583 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Clinical Study on the Safety and Efficacy of Chimeric Antigen Receptor T Cell Injection Targeting CD19 Gene in the Treatment of Refractory Systemic Lupus Erythematosus
Renal Arterial Resistive Index as a Noninvasive Biomarker of Disease Activity in Lupus Nephritis Patients
Evaluation of Uromodulin as a Biomarker of Renal Histological Activity/ Chronicity Indices in Lupus Nephritis
Who cites it
583 citing papers in PubMed, 5 syntheses or guidelines pooled it, 871 citations in OpenAlex.
- Galectin-3 in systemic lupus erythematosus: a meta-analysis.Immunologic research · 2026Pooled it
- Global prevalence, site-specific patterns, and key risk factors for osteoporosis and bone loss in systemic lupus erythematosus: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- Transitioning from invasive to liquid biopsy techniques: a bibliometric analysis and prospective insights on biomarkers in lupus nephritis.Frontiers in medicine · 2026Pooled it
- Lupus nephritis in Africa: a systematic review of case reports and case series.BMC nephrology · 2025Pooled it
- Circulating MiRNAs as diagnostic biomarkers of lupus nephritis in patients with systemic lupus erythematosus: a systematic review and meta-analysis.Scientific reports · 2025Pooled it
- The Renal Activity Index for Lupus: Validation for Prediction of Kidney Inflammation in Adult Patients With Lupus Nephritis.The Journal of rheumatology · 2026Trial
- Trial
- Trial
- Evaluation of clinicopathological features of renal biopsies in non-lupus rheumatic diseases: a university hospital experience.Renal failure · 2026Article
- Resetting immunometabolic set points in autoimmune disease.Journal of translational autoimmunity · 2026Review
- Clinical presentations, treatments, and outcomes of pediatric lupus nephritis: a prospective cohort study from the Pediatric Nephrology Research Consortium.Pediatric nephrology (Berlin, Germany) · 2026Article
- Lupus Nephritis Susceptibility Loci in theKidney international reports · 2026Article
- Macrophage pyroptosis in lupus nephritis - Novel insights into renal pathogenesis and clinical correlates: A cross-sectional study.Medicine · 2026Observational
- An explainable hybrid SMPR-Net-XGBoost framework for automated lupus nephritis detection using medical image analysis.International urology and nephrology · 2026Article
- Identification and functional characterisation of SCO1 as a mitochondria-related biomarker in lupus nephritis.Lupus science & medicine · 2026Article
- Efficacy and safety of telitacicept combined with standard of care in patients with proliferative lupus nephritis: a real-world retrospective study.Lupus science & medicine · 2026Article
- An Automated, Ventana Discovery Platform-based Imaging Workflow for Simultaneous Quantification of B Cells, Plasma Cells, and Plasmablasts in FFPE Human Tissues.Bio-protocol · 2026Article
- Refractory lupus nephritis: national multicenter study.Internal and emergency medicine · 2026Article
- Genetic and epigenetic determinants of relapse risk in lupus nephritis.Lupus science & medicine · 2026Article
- Peripheral Blood Neutrophil-to-Lymphocyte Ratio Combined With Fibrinogen-to-Albumin Ratio Assists in Identifying Systemic Lupus Erythematosus Activity and Lupus Nephritis.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2026Article
523 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lupus nephritis (LN) is a form of glomerulonephritis that constitutes one of the most severe organ manifestations of the autoimmune disease systemic lupus erythematosus (SLE). Most patients with SLE who develop LN do so within 5 years of an SLE diagnosis and, in many cases, LN is the presenting manifestation resulting in the diagnosis of SLE. Understanding of the genetic and pathogenetic basis of LN has improved substantially over the past few decades. Treatment of LN usually involves immunosuppressive therapy, typically with mycophenolate mofetil or cyclophosphamide and with glucocorticoids, although these treatments are not uniformly effective. Despite increased knowledge of disease pathogenesis and improved treatment options, LN remains a substantial cause of morbidity and death among patients with SLE. Within 10 years of an initial SLE diagnosis, 5-20% of patients with LN develop end-stage kidney disease, and the multiple comorbidities associated with immunosuppressive treatment, including infections, osteoporosis and cardiovascular and reproductive effects, remain a concern. Clearly, early and accurate diagnosis of LN and prompt initiation of therapy are of vital importance to improve outcomes in patients with SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.